XCath Raises $30M in Series C Funding to Advance Neuro-Endovascular Surgical Robotics

In the world of neurovascular medicine, the difference between hesitation and precision can be measured in millimeters. That is exactly where XCath has chosen to build its edge. Inside Houston’s Texas Medical Center, a team rooted in the University of Texas Medical School lineage has been engineering robotic tools designed to navigate the brain’s tightest corridors. Founded in 2017, XCath focuses on endovascular robotics that help physicians guide devices through complex cerebral vessels with the kind of control that delicate intracranial procedures demand.

Now the market just leaned a little closer to the operating table. XCath secured $30M in Series C funding, bringing total capital raised to $92M. The round was co led by Crescent Enterprises and Dr. Fred Moll, who also serves as Chairman of the XCath Board of Directors. When someone like Dr. Fred Moll shows up with conviction and capital, people in medical robotics tend to pay attention. The plan for the new capital is clear. Continue developing the EVR endovascular robotic system, push toward commercialization, and advance a clinical telerobotic mechanical thrombectomy that could extend life saving stroke care beyond the physical reach of specialists.

But the real signal here is not just the funding. It is the clinical proof already unfolding. XCath’s robotic system recently completed first in human brain aneurysm procedures at The Panama Clinic in Panama City. 3 complex aneurysm cases. The EVR system navigated cerebral vessels with sub millimeter accuracy while physicians deployed commercially available devices such as flow diverting stents and intrasaccular implants. 2 of those procedures were completed consecutively in just over 4 hours using a monoplane angiographic imaging system. For anyone who understands how delicate intracranial navigation can be, that is not just impressive. That is a glimpse of a different operating room.

Credit where it is due. Congratulations to CEO Eduardo Fonseca and the XCath team for pushing this technology forward with the kind of patience and discipline that serious medical innovation demands. Also a nod to Crescent Enterprises and Dr. Fred Moll for backing a company working in one of the toughest and most meaningful frontiers in healthcare.

From Houston to Pangyo, South Korea, XCath is building something that could quietly change how neurovascular care travels across the world. When robotics can guide a catheter through the brain with this level of control, distance begins to matter a little less and access begins to matter a lot more. And in stroke and aneurysm care, that difference can mean everything.